ArticleThe oncologist2022

Modeling the Cost-Effectiveness of Adjuvant Osimertinib for Patients with Resected EGFR-mutant Non-Small Cell Lung Cancer.

Christopher A Lemmon et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.